ASXL3 gene mutations inhibit cell proliferation and promote cell apoptosis in mouse cardiomyocytes by upregulating lncRNA NONMMUT063967.2

• Published in: Biochemistry and biophysics reports Vol. 35; p. 101505
• Main Authors: Liu, Zequn, Jiang, Yanmin, Fang, Fu, Li, Ru, Han, Jin, Yang, Xin, Deng, Qiong, Li, Lu-Shan, Lei, Ting-ying, Li, Dong-Zhi, Liao, Can
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.09.2023; Elsevier
• Subjects: ASXL3 gene mutations; Cardiomyocytes; cell proliferation and apoptosis; lncRNA; ASXL3 gene mutations; cell proliferation and apoptosis; Cardiomyocytes; lncRNA
• ISSN: 2405-5808; 2405-5808
• DOI: 10.1016/j.bbrep.2023.101505

Congenital heart disease (CHD) is a serious condition with unknown etiology. In a recent study, a compound heterozygous mutation (c.3526C > T [p.Arg1176Trp] and c.4643A > G [p.Asp1548Gly]) in the ASXL3 gene was identified, which is associated with CHD. This mutation was overexpressed in HL-1 mouse cardiomyocyte cells, leading to increased cell apoptosis and decreased cell proliferation. However, whether this effect is mediated by long noncoding RNAs (lncRNAs) is yet to be determined. We identified the differences among lncRNA and mRNA profiles in mouse heart tissues using sequencing to explore this issue. We detected HL-1 cell proliferation and apoptosis through CCK8 and flow cytometry. Fgfr2, lncRNA, and Ras/ERK signaling pathway expressions were evaluated using quantitative real time polymerase chain reaction (qRT-PCR) and western blot (WB) assays. We also conducted functional investigations by silencing lncRNA NONMMUT063967.2. The sequencing revealed significant changes in lncRNA and mRNA profiles, with the expression of lncRNA NONMMUT063967.2 being significantly promoted in the ASXL3 gene mutations group (MT) while the expression of Fgfr2 being downregulated. The in vitro experiments showed that ASXL3 gene mutations inhibited the proliferation of cardiomyocytes and accelerated cell apoptosis by promoting the expression of lncRNAs (NONMMUT063967.2, NONMMUT063918.2, and NONMMUT063891.2), suppressing the formation of FGFR2 transcripts, and inhibiting the Ras/ERK signaling pathway. The decrease in FGFR2 had the same effect on the Ras/ERK signaling pathway, proliferation, and apoptosis in mouse cardiomyocytes as ASXL3 mutations. Further mechanistic studies revealed that suppression of lncRNA NONMMUT063967.2 and overexpression of FGFR2 reversed the effects of the ASXL3 mutations on the Ras/ERK signaling pathway, proliferation, and apoptosis in mouse cardiomyocytes. Therefore, ASXL3 mutation decreases FGFR2 expression by upregulating lncRNA NONMMUT063967.2, inhibiting cell proliferation and promoting cell apoptosis in mouse cardiomyocytes. •ASXL3 mutation inhibits cell proliferation and induce apoptosis in mouse cardiomyocytes.•ASXL3 mutation alters the splice of Fgfr2.•ASXL3 mutation actives the Ras/ERK signaling pathway.•ASXL3 mutation promotes the expression of NONMMUT063967.2.•Inhibition of NONMMUT063967.2 negates the effects of ASXL3 mutations.